Sign in

You're signed outSign in or to get full access.

Melissa Benson

Research Analyst at Barrenjoey

Dr. Melissa Benson is Head of Emerging Healthcare Equity Research at Barrenjoey, specializing in innovative healthcare companies within the emerging biotech sector. She covers specific firms such as Immutep and delivers in-depth equity research reports, though detailed public performance metrics like success rates or TipRanks rankings are not widely available. Benson joined Barrenjoey in late 2024 after more than five years of experience covering the healthcare sector at prior firms. She holds a doctorate (Dr.) and relevant professional credentials for equity research analysis.

Melissa Benson's questions to Telix Pharmaceuticals (TLX) leadership

Question · H2 2025

Melissa Benson inquired about the agreed deliverables with the FDA for the Zircaix BLA resubmission, specifically whether new clinical data is required or if the focus is on preclinical and analytical data.

Answer

Christian Behrenbruch, CEO and Managing Director of Telix Pharmaceuticals, stated that most CMC remediation topics involve laboratory, manufacturing, and process documentation. He confirmed that a deliverable regarding comparability between research-grade and commercial-scale material is well in hand and not a material time delay, implying no new clinical data is required.

Ask follow-up questions

Fintool

Fintool can predict Telix Pharmaceuticals logo TLX's earnings beat/miss a week before the call

Question · H2 2025

Melissa Benson inquired about the agreed deliverables with the FDA for the Zircaix BLA, specifically asking if new clinical data is required or if it primarily involves preclinical and analytical data.

Answer

CEO Christian Behrenbruch stated that most CMC remediation topics for Zircaix involve laboratory, manufacturing, and process documentation. A deliverable on comparability between research-grade and commercial-scale material is already in hand and will not materially delay the resubmission.

Ask follow-up questions

Fintool

Fintool can write a report on Telix Pharmaceuticals logo TLX's next earnings in your company's style and formatting